---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-122300"
form_type: "8-K"
ticker: "RGNX"
cik: "0001590877"
company_name: "REGENXBIO Inc."
filed_at: "2024-11-06T23:59:59+00:00"
generated_at: "2026-05-30T04:33:41.871664+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# REGENXBIO Q3 net loss $59.6M; cash $278.6M; RGX-202 pivotal trial initiation expected this month

## Summary
- Net loss of $59.6M ($1.17 EPS) vs $61.9M ($1.41 EPS) in Q3 2023.
- Revenue $24.2M, down from $28.9M, driven by lower Zolgensma royalties ($23.9M vs $28.4M).
- Cash, cash equivalents and marketable securities $278.6M as of Sep 30, 2024.
- RGX-202 pivotal trial initiation and first functional data expected November 2024.
- BLA submission for RGX-121 (MPS II) initiated, expected completion Q1 2025.

## SEC filing metadata
- accession: 0000950170-24-122300
- form_type: 8-K
- ticker: RGNX
- cik: 0001590877
- company_name: REGENXBIO Inc.
- filed_at: 2024-11-06T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1590877/000095017024122300/0000950170-24-122300-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1590877/000095017024122300/rgnx-20241106.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-122300
- JSON: https://secwatch.observer/filing/0000950170-24-122300.json
- Plain text: https://secwatch.observer/filing/0000950170-24-122300.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.